Profile data is unavailable for this security.
About the company
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
- Revenue in AUD (TTM)2.83m
- Net income in AUD-4.88m
- Incorporated2015
- Employees1.00k
- LocationNoxopharm LtdSuite 71, 159 Ridgecrop DriveCASTLE HILL 2154AustraliaAUS
- Phone+61 29144-2223
- Fax+61 29199-9600
- Websitehttps://www.noxopharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimeric Therapeutics Ltd | 3.97m | -10.43m | 11.05m | -- | -- | 2.68 | -- | 2.78 | -0.0071 | -0.0071 | 0.0029 | 0.0009 | 0.2154 | -- | 1.73 | -- | -56.62 | -66.67 | -171.92 | -112.02 | 78.66 | -- | -262.83 | -2,013.07 | -- | -62.30 | 0.7162 | -- | -- | -- | 16.76 | -- | -- | -- |
| Adalta Ltd | 695.66k | -4.50m | 11.47m | -- | -- | -- | -- | 16.49 | -0.0059 | -0.0059 | 0.0009 | -0.0005 | 0.1804 | -- | 0.4992 | -- | -116.72 | -70.41 | -216.60 | -126.24 | -- | -- | -647.19 | -207.18 | -- | -75.41 | 1.51 | -- | -61.02 | -28.97 | 16.33 | -- | -- | -- |
| Imagion Biosystems Ltd | 1.06m | -2.20m | 12.26m | -- | -- | -- | -- | 11.62 | -0.0177 | -0.0177 | 0.0082 | -0.0192 | 1.45 | -- | 1,173.13 | -- | -302.58 | -76.63 | -- | -102.36 | -- | -- | -208.52 | -911.24 | -- | -0.7972 | -- | -- | -18.54 | 22.02 | 83.43 | -- | -- | -- |
| Nexsen Ltd | -100.00bn | -100.00bn | 12.96m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.44 | -- | -605,140.90 | -- | -- | -- |
| Cambium Bio Ltd | 670.05k | -3.84m | 13.09m | -- | -- | 5.68 | -- | 19.54 | -0.3489 | -0.3489 | 0.0596 | 0.1004 | 0.1498 | -- | 2.58 | -- | -85.96 | -41.30 | -146.56 | -75.44 | 70.04 | -- | -573.73 | -118.71 | -- | -- | 0.2082 | -- | 419.43 | -16.63 | -70.42 | -- | -- | -- |
| BPH Energy Ltd | 836.64k | 6.79m | 17.60m | 2.00k | 2.29 | 0.4098 | -- | 21.04 | 0.0057 | 0.0057 | 0.0007 | 0.0317 | 0.0241 | -- | 10.59 | -- | 19.54 | 9.05 | 19.92 | 9.45 | -- | -- | 811.09 | 431.04 | -- | -- | 0.0022 | -- | -0.8344 | 28.34 | 48.93 | 43.33 | -- | -- |
| Neurotech International Ltd | 2.58m | -10.60m | 18.15m | -- | -- | 4.97 | -- | 7.03 | -0.0103 | -0.0103 | 0.0025 | 0.0028 | 0.3341 | -- | 12.69 | -- | -137.17 | -130.68 | -142.71 | -148.27 | 4.41 | -- | -410.57 | -428.93 | 11.34 | -- | 0.00 | -- | -22.61 | 99.30 | -109.08 | -- | -- | -- |
| Patrys Ltd | 828.54k | -3.01m | 18.72m | 15.00 | -- | 10.61 | -- | 22.60 | -0.0156 | -0.0156 | 0.0043 | 0.0033 | 0.2808 | -- | 0.7647 | -- | -102.13 | -58.09 | -143.30 | -63.36 | -- | -- | -363.69 | -250.93 | -- | -- | 0.00 | -- | -40.57 | 1.40 | 14.86 | -- | -- | -- |
| IDT Australia Ltd | 19.86m | -8.06m | 19.45m | 156.00 | -- | 0.8932 | -- | 0.9792 | -0.0189 | -0.0189 | 0.0465 | 0.0509 | 0.5817 | 2.60 | 2.59 | -- | -23.61 | -13.43 | -29.19 | -16.06 | 69.19 | 79.42 | -40.60 | -30.01 | 2.36 | -9.62 | 0.3222 | -- | 40.65 | 6.99 | -48.96 | -- | 11.30 | -- |
| Noxopharm Ltd | 2.83m | -4.88m | 20.46m | 1.00k | -- | 29.65 | -- | 7.23 | -0.0167 | -0.0167 | 0.0097 | 0.0024 | 0.4979 | -- | 1.06 | -- | -85.95 | -49.70 | -156.33 | -59.16 | -- | -- | -172.63 | -229.01 | -- | -- | 0.7823 | -- | 17.54 | -19.45 | -36.50 | -- | -- | -- |
| BTC Health Ltd | 9.96k | 3.98m | 24.66m | 1.00 | 5.92 | 2.45 | 6.20 | 2,476.34 | 0.0117 | 0.0117 | 0.00003 | 0.0282 | 0.0014 | -- | -- | -- | 54.89 | -13.71 | 56.47 | -14.66 | -- | -- | 39,972.79 | -3,966.34 | -- | -- | 0.00 | -- | -39.12 | -43.28 | 277.27 | -- | -- | -- |
| Holista Colltech Limited | 5.83m | 584.85k | 30.53m | 3.00 | 37.73 | -- | 47.21 | 5.24 | 0.0022 | 0.0023 | 0.0195 | -0.0016 | 1.76 | 3.83 | 5.84 | -- | 17.53 | -46.13 | -- | -85.40 | 49.66 | 55.15 | 9.98 | -38.85 | 0.3782 | 3.93 | -- | -- | -5.82 | -5.07 | 97.92 | -- | -37.01 | -- |
